BOOM
Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one {Luteolin} - Escherichia coli PA49 |
👶
Therapeutic administration of Luteolin protects against Escherichia coli-derived Lipopolysaccharide-triggered inflammatory response and oxidative injury. Acta tropica (Acta Trop ) Vol: 255 Issue Pages: 107236 Pub: 2024 Jul Epub: 2024 Apr 29 Authors Shaukat A , Rajput SA , Ali M , Shukat R , Hanif S , Hassan M , Fouad D , Ataya FS , Shaukat I , Yousaf A , Shaukat S , Su RW , Publication |
| 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one {Luteolin} - Escherichia coli PA49 |
👶
Dietary flavonoid luteolin attenuates uropathogenic Escherichia. Coli invasion of the urinary bladder. BioFactors (Oxford, England) (Biofactors ) Vol: 42 Issue 6 Pages: 674-685 Pub: 2016 Nov 12 Epub: 2016 Jul 25 Authors Shen XF , Teng Y , Sha KH , Wang XY , Yang XL , Guo XJ , Ren LB , Wang XY , Li J , Huang N , Publication |
| 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one {Luteolin} - Escherichia coli PA49 |
👶
Synthesis and biological evaluation of novel luteolin derivatives as antibacterial agents. European journal of medicinal chemistry (Eur J Med Chem ) Vol: 44 Issue 2 Pages: 908-14 Pub: 2009 Feb Epub: 2008 Jan 25 Authors Lv PC , Li HQ , Xue JY , Shi L , Zhu HL , Publication |
| 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one {Luteolin} - Escherichia coli PA49 |
👶
Development of Luteolin-Loaded Calcium Alginate and Gum Tragacanth Blend Microbeads for Oral Delivery: In Vitro Characterization, Antioxidant, Antimicrobial, and Anticancer Activity Against Colon Cancer Cell Line (HT-29). Assay and drug development technologies (Assay Drug Dev Technol ) Vol: Issue Pages: Pub: 2025 Apr 4 Epub: 2025 Apr 4 Authors Zafar A , Alsaidan OA , Mujtaba MA , Sultana S , Publication |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
